Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
08:03pWe discuss $GILD CAR-T approval, up next on @PowerLunch
1
07:40pFDA approves Gilead cancer gene therapy; price set at $373,000
2
07:20p35 Stocks Moving In Thursday's Mid-Day Session
3
07:03p50 most #liquid, high #RelativeStrength #stocks in the #market $AABA $BABA $B.. 
06:51pGilead Kite's treatment becomes first FDA approved CAR-T therapy #KitePharma,.. 
06:50pGilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug  
06:35pGilead receives FDA approval for Kite's breakthrough CAR-T therapy for .. 
06:07pGilead shares climb after its L.A.-area Kite unit gets FDA approval for lymph.. 
06:04pLIVE: Gilead gains 4% after FDA approves lymphoma drug $GILD -
4
05:59pGilead: A New Cancer Drug! Great…But You Still Overpaid for Kite  
05:57pGilead cell-therapy drug Yescarta gets FDA approval
1
05:55pICYMI following Wed's mkt close: Another CAR-T rides into town as FDA approva.. 
05:53pGilead gets FDA go-ahead for second CAR-T . Read more about the $12 bln deal ..
4
05:19pWATCH: Stocks we're watching today - $VZ, $AXP, $NKE, $APRN, $GILD
3
04:53pGilead Sciences Yescarta Drug Approved By FDA  
04:39pA Kite-Gilead #cancer treatment that's part of 'a big new field of medicine' .. 
04:37pGilead: A New Cancer Drug! Great?But You Still Overpaid for Kite  
04:26pFDA approves Gilead cancer gene therapy; price set at $373,000  
04:23pThe FDA approves the Gilead's Yescarta lymphoma cancer therapy drug
4
04:17pFDA approves Gilead cancer gene therapy; price set at $373,000
2
04:14pMove over, Novartis: Kite and Gilead break into CAR-T market with early axi-c.. 
04:10pFDA approves Gilead cancer gene therapy; price set at $373,000
2
03:51pPharmalot.. Pharmalittle.. Good Morning.. Novo pins hopes on newly approved d.. 
03:47pOn The Fly: Pre-market Movers $VZ $DHR $BX $DGX $LLNW $URI $GILD $BLFS $ONCE .. 
03:40p#Stocks to Watch today: $VZ, $AXP, $NKE, $APRN, $GILD
5
03:37pGilead Jumps After FDA Approves Its Kite-Acquired CAR-T Drug
1
03:30pFDA approves Gilead cancer gene therapy; price set at $373,000
3
03:25pICYMI: $GILD breaks into CAR-T market with Yescarta approval
1
03:17pmorning game plan. $ADBE $GILD $EBAY $UAL to watch our am meeting live ??
1
03:15pGilead Sciences shares bolstered after FDA approval validates Kite Pharma mer.. 
03:02pMorning Movers: Gilead Gains, Nike Drops, Philip Morris Tumbles  
03:00p  
02:53pPre-mkt movers/news | via CNBC $ADBE $UAL $EBAY $APRN $TSM $TRV $VZ $NKE $BX..
1
02:50pFDA approves Gilead cancer gene therapy; price set at $373,000
41
02:46pFDA approves Gilead cancer gene therapy; price set at $373,000
8
02:35pU.S. FDA approves Gilead cancer gene therapy; price set at $373,000
2
02:35p22 Stocks Moving In Thursday's PreMarket
3
02:35pFDA approves Gilead cancer gene therapy; price set at $373,000
11
02:26pBuying in Gilead (Kite Pharma) spreads to Juno, up 2% premarket  
02:21pGilead Sciences's buy rating reiterated at Berenberg Bank. $96.00 PT.  
02:16pVerizon Communications, Gilead Sciences, Alcoa Corp, PayPal Holdings - PRE-MA.. 
02:13p$GILD (+2.0% pre) FDA follows through with a groundbreaking OK for Yescarta, ..
1
02:10pGilead faces patent battle with Juno over Yescarta, says Morgan Stanley $JUNO..
1
01:58p"He refused The Handmaid’s Tale, too – presumably because those Gilead robes ..
1
01:43pWe discuss $GILD Yescarta approval, coming up on @SquawkCNBC 
01:38pBerenberg Bank Releases a Buy Rating on Gilead Sciences $GILD  
01:16p$GILD gets FDA approval for CAR-T cell based gene therapy, shares moving up $..
2
01:10p  
01:00p  
12:56pGilead shares rise 3% on FDA approval of cell therapy #news 
More tweets
Qtime:509
Financials ($)
Sales 2017 25 859 M
EBIT 2017 16 072 M
Net income 2017 10 607 M
Debt 2017 12 394 M
Yield 2017 2,64%
P/E ratio 2017 10,00
P/E ratio 2018 12,11
EV / Sales 2017 4,52x
EV / Sales 2018 5,02x
Capitalization 104 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 84,2 $
Spread / Average Target 5,2%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.73%104 487
REGENERON PHARMACEUTICALS19.69%47 079
VERTEX PHARMACEUTICALS110.07%39 018
ACTELION23.81%29 869
GENMAB14.75%12 912
EXELIXIS, INC.84.64%8 091